osimertinib + simvastatin

Osimertinib + simvastatin is a combination of two small molecule drugs. Osimertinib is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). It irreversibly inhibits both EGFR-sensitizing and T790M resistance mutations. Simvastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and prevent cardiovascular disease. The combination has been studied in the context of advanced NSCLC to assess potential drug-drug interactions and possible synergistic effects on tumor biology. Clinical studies indicate that osimertinib does not significantly alter the pharmacokinetics of simvastatin, suggesting minimal risk for clinically relevant drug-drug interactions[1][2]. Preclinical data suggest that simvastatin may help overcome acquired resistance to EGFR-TKIs like osimertinib in certain cellular contexts by reversing epithelial-mesenchymal transition (EMT) associated with mutant p53 expression[5].

Other names

osimertinib + simvastatin